Disease-modifying therapies for multiple sclerosis involve the use of interferon-based immunomodulatory drugs such as glatiramer acetate, fingolimod, teriflunomide and natalizumab, each with its own success rate and list of side effects. The goal of these drugs is to prolong the time to relapse and reduce brain lesions. Over the last decade, there has been a surge in awareness of new treatments for MS that include Low Dosages of Naltrexone (LDN). A website based in the United Kingdom, LDN now, serves as a reliable source of qualified and peer reviewed knowledge to help patients, family support, clinicians understand this new bio therapeutic approach for treatment of MS and avoid the pitfalls of internet misinformation. The website posts scientific publications, clinical trials, and patient feedback for an expanding population of MS patients taking LDN successfully McLaughlin PJ, Zagon IS, A New Biotherapeutic Approach for the Treatment of Multiple Sclerosis.
Being a thrust area in multiple sclerosis disease management this topic is handled in all the issues of journal as a prominent issue. The journal of multiple sclerosis articles thus serves as a reference for the readers as well as doctors in identifying various treatment modalities used in the disease management.
Last date updated on November, 2020